Two Sigma Investments, LP Freeline Therapeutics Holdings PLC Transaction History

Two Sigma Investments, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.42 - $0.63 $252 - $378	-600 Reduced 1.38%	43,005 $19,000
Q4 2022 Feb 14, 2023	SELL	$0.46 - $0.73 $3,358 - $5,329	-7,300 Reduced 14.34%	43,605 $20,000
Q3 2022 Nov 14, 2022	SELL	$0.69 - $1.1 $11,823 - $18,849	-17,136 Reduced 25.18%	50,905 $36,000
Q2 2022 Aug 15, 2022	SELL	$0.69 - $1.12 $44,698 - $72,554	-64,781 Reduced 48.77%	68,041 $59,000
Q1 2022 May 16, 2022	BUY	$0.92 - $2.03 $84,409 - $186,250	91,749 Added 223.38%	132,822 $149,000
Q4 2021 Feb 14, 2022	SELL	$1.97 - $3.45 $88,425 - $154,856	-44,886 Reduced 52.22%	41,073 $81,000
Q3 2021 Nov 15, 2021	BUY	$3.04 - $8.9 $261,315 - $765,035	85,959 New	85,959 $293,000

30.1K

Ticker FRLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,972,300
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.